ARTICLE | Clinical News
Invega Sustenna regulatory update
March 14, 2011 7:00 AM UTC
The European Commission approved an MAA for Xeplion paliperidone palmitate from Johnson & Johnson for the maintenance treatment of schizophrenia in adult patients stabilized with paliperidone or rispe...